Makers Laboratories Limited (MAKERSL) Fair Value & Analysis
Healthcare · IN · Market cap ₹894M
Fair value as of: Jul 5, 2026
From 26 valuation models · updated today
Share price −2.3% over the past month.
Price vs Fair Value (12 months)
12‑month range ₹112.05 – ₹176.45 · fair‑value band ₹64.01 – ₹99.63 · the ₹151.45 price screens above the ₹85.19 fair value. As of Jul 5, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Makers Laboratories Limited (MAKERSL) currently trades at ₹151.45, while our model-based Fair Value estimate is ₹85.19 — implying the stock looks roughly 43.8% overvalued today. We read business quality at 60/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).
Over the trailing twelve months, Makers Laboratories Limited generated revenue of ₹1.4B at a net margin of 1.7%. Revenue grew 5.5% year over year. It earns a return on equity of 6.6%. Net debt stands at ₹45.7M. Fundamentals as of Jul 5, 2026
Our scenario range runs from ₹64.01 (bear case) to ₹99.63 (bull case); at ₹151.45, the current price sits above that range. The share trades about 19% below its 52-week high and 39% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -44% fair-value upside — at -44%, MAKERSL screens cheaper than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 5, 2026. TTM = trailing twelve months.
About the company
Makers Laboratories Limited, an integrated pharmaceutical company, manufactures and markets formulations in India. The company offers general health therapeutic products, such as acid regulatory, anthelmintic, anti-allergic, anti-asthmatic, anti-biotic, anti-diabetics, anti-diarrhoeals, anti-emetics and anti-nauseants, anti-fungal, anti-hypertensive, anti"inflammatory, analgesic, anti-spasmodic, anti-malarial, and anti-thyroid. It also provides cough and cold control, digestives, neurotonics, nutritional supplements, topical anti-biotic/anti-microbial, and other specialties drugs. The company sells its products under the Duramol, Artemak-AB, Loroquin, Nimuwin, Coffwin, and Exylin brand names. It distributes its products through agents, stockiest, doctors, and retailers. Makers Laboratories Limited was incorporated in 1984 and is based in Mumbai, India.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Makers Laboratories Limited reported revenue of ₹1.4B in FY2026 versus ₹1.3B in FY2022, a compound +2.7%/yr. Reported net income was ₹23.5M in FY2026, compounding −17.1%/yr from FY2022.
Is MAKERSL fairly valued? → Check now
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 5, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 1276 | HK$57.85 | HK$29.84 | -48% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,786 | ₹991.46 | -44% |
| Zoetis Inc Z1TS34 | R$25.93 | R$19.70 | -24% |
| Hansoh Pharmaceutical Group 3692 | HK$29.30 | HK$23.90 | -18% |
| Divi's Laboratories Limited DIVISLAB | ₹6,639 | ₹1,281 | -81% |
| Torrent Pharmaceuticals Limited TORNTPHARM | ₹4,421 | ₹1,504 | -66% |
| Cipla Limited CIPLA | ₹1,416 | ₹1,466 | +4% |
| Zydus Lifesciences Limited ZYDUSLIFE | ₹1,089 | ₹841.98 | -23% |
| Dr. Reddy's Laboratories Limited DRREDDY | ₹1,278 | ₹595.34 | -53% |
| PharmaEssentia Corporation 6446 | 1,095 TWD | 365.87 TWD | -67% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Makers Laboratories Limited (MAKERSL) undervalued?
What is the fair value of MAKERSL?
What is the quality score of MAKERSL?
What is the revenue of Makers Laboratories Limited (MAKERSL)?
What is the net profit margin of MAKERSL?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.